Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: Authors' reply

BMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7450.1260 (Published 20 May 2004) Cite this as: BMJ 2004;328:1260
  1. Christopher V Plowe, associate professor (cplowe@medicine.umaryland.edu),
  2. James G Kublin, clinical instructor,
  3. Fraction K Dzinjalamala, research associate,
  4. Deborah S Kamwendo, research associate,
  5. Rabia A G Mukadam, research associate,
  6. Phillips Chimpeni, clinical officer,
  7. Malcolm E Molyneux, professor,
  8. Terrie E Taylor, professor
  1. Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1-480, Baltimore, MD 21044, USA
  2. Blantyre Malaria Project, College of Medicine, University of Malawi, Blantyre, Malawi
  3. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi
  4. College of Osteopathic Medicine, Michigan State University, Lansing, MI, USA

    EDITOR—How to reconcile our article's report of a sustained 80% efficacy with White's assertion that we found cure rates of less than 40%? We used the World Health Organization's standard definition of antimalarial therapeutic efficacy in high transmission areas, which is based on follow up through 14 days after treatment.1 We also reported parasitaemia prevalences at 28 days after treatment, but these data do not provide cure rates in any accepted or standard sense. In high transmission settings, the “cure rate” declines as follow-up …

    View Full Text

    Sign in

    Log in through your institution